Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro

Blood

Volumn 99, Issue 2, 2002, Pages 664-671

  Mow, Benjamin M F ^a,b,c   Chandra, Joya ^a,b,c   Svingen, Phyllis A ^a,b,c   Hallgren, Christopher G ^a,b,c   Weisberg, Ellen ^a,b,c   Kottke, Timothy J ^a,b,c   Narayanan, Ven L ^a,b,c   Litzow, Mark R ^a,b,c   Griffin, James D ^a,b,c   Sausville, Edward A ^a,b,c   Tefferi, Ayalew ^a,b,c   Kaufmann, Scott H ^a,b,c  

^a MAYO CLINIC   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPHOSTIN; BCR ABL PROTEIN; CASPASE; IMATINIB; PROTEIN BCL X; PROTEIN KINASE INHIBITOR; PROTEIN MCL 1; STAT5 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG RESISTANCE; ENZYME ACTIVATION; GRANULOCYTE; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION;

EID: 0037079720     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.2.664     Document Type: Article

References (57)

1. Chronic myeloid leukemia
2. Kantarjian hours, Kurzrock R. The BCR gene and Philadelphia chromosome-positive leukemogenesis
3. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage-colony-stimulating factor in mice: A novel model for chronic myelogenous leukemia
4. Growth factor independence and BCR/ABL transformation: Promise and pitfalls of murine model systems and assays
5. The molecular biology of chronic myeloid leukemia
6. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3
7. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs
8. Inhibition of apoptosis by Bcr-Abl in chronic myeloid leukemia
9. Bcr-Abl maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death
10. Chronic myelogenous leukemia: Update on biology and treatment
11. The biology and treatment of chronic myelogenous leukemia
12. Effect of herbimycin A, an antagonist of tyrosine kinase, on Bcr/Abl oncoprotein-associated cell proliferations: Abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210Bcr/Abl and preferential inhibition on Ph1-positive leukemia cell growth
13. bcr-abl tyrosine kinase activity induces K562 to differentiate
14. Tyrphostin induced growth inhibition: Correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia
15. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
16. The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells
17. Status of Bcr-Abl tyrosine kinase inhibitors in chronic myelogenous leukemia
18. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
19. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
20. Abl protein-tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
21. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
22. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
23. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
24. Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells
25. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents
26. Tyrphostins: Tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction
27. Altered physical state of p210bcr/abl in tyrphostin AG957-treated K562 cells
28. Effects of the Bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro
29. cbl phosphorylation in anti-CD-3-stimulated T-lymphoblasts
30. + chronic myelogenous leukemia progenitor cells
31. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
32. Human bone marrow colony growth in agar-gel
33. Altered formation of topotecan-stabilized topolsomerase I-DNA adducts in human leukemia cells
34. Erasure of Western blots after autoradiographic or chemiluminescent detection
35. Electroporation in "intracellular" buffer increases cell survival
36. Phosphotyrosine antibodies identify the p210c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cells
37. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl
38. P210 and P190 (BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members
39. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization
40. Target protease specificity of the viral serpin CrmA: Analysis of five caspases
41. Biochemical pathways of caspase activation during apoptosis
42. Mammalian caspases: Structure, activation, substrates and functions during apoptosis
43. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL
44. A requirement for NF-κB activation in Bcr-Abl-mediated transformation
45. Nuclear factor (NF)-κB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor α-induced apoptosis
46. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
47. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression
48. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P21Obcr/abl protein
49. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: Protection is correlated with up regulation of Bcl-xL
50. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
51. Selection and characterization of Bcr-Abl positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
52. MCL-1, a member of the BCL-2 family, is induced rapidly in response to signals for cell differentiation or death, but not to signals for cell proliferation
53. Induction of Bcl-2 family member Mcl-1 as an early response to DNA damage
54. The protooncogene produce p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway
55. BCR/ABL gene amplification: A possible mechanism of drug resistance in patients treated with an Abl-specific kinase inhibitor
56. Detection of resistance to STI571 in patients with Bcr-abl positive acute leukemia and chronic myeloid leukemia blast crisis